[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100629772":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":10,"centralContacts":14,"locations":25,"responsibleParty":75,"collaborators":10,"id":77,"slug":78,"hasResults":79,"nctId":80,"briefTitle":81,"officialTitle":81,"acronym":82,"eligibilityCriteria":83,"healthyVolunteers":79,"sex":84,"minAge":85,"maxAge":86,"enrollmentInfo":87,"targetDuration":10,"studyType":90,"phases":10,"briefSummary":91,"conditions":92,"keywords":94,"overallStatus":97,"whyStopped":10,"lastUpdateSubmitDate":98,"lastUpdatePostDateStruct":99,"startDateStruct":102,"completionDateStruct":104,"leadSponsor":106,"locationsCount":107},{"fullName":5,"class":6},"University Hospital, Tours","OTHER",[8,12],{"label":9,"type":10,"description":11,"interventionNames":10},"ALS patients",null,"Biological:\n\nA blood sample will be taken at the time of inclusion by increasing the volume taken for the health routine care.",{"label":13,"type":10,"description":11,"interventionNames":10},"control patients with another motor neuron disease",[15,21],{"name":16,"role":17,"phone":18,"phoneExt":19,"email":20},"Hélène BLASCO, Pr","CONTACT","234378911","+33","helene.blasco@univ-tours.fr",{"name":22,"role":17,"phone":23,"phoneExt":19,"email":24},"Noémie EYRAUD","247478060","n.eyraud@chu-tours.fr",[26,45,60],{"facility":27,"status":10,"city":28,"state":10,"zip":29,"country":30,"countryCode":31,"cosmosGeoPoint":32,"geoPoint":37,"contacts":38},"University hospital, Limoges","Limoges","87000","France","FR",{"type":33,"coordinates":34},"Point",[35,36],1.24759,45.83362,{"lat":36,"lon":35},[39,43],{"name":40,"role":17,"phone":41,"phoneExt":19,"email":42},"Philippe COURATIER, Pr","555056559","philippe.couratier@chu-limoges.fr",{"name":40,"role":44,"phone":10,"phoneExt":10,"email":10},"PRINCIPAL_INVESTIGATOR",{"facility":46,"status":10,"city":47,"state":10,"zip":48,"country":30,"countryCode":31,"cosmosGeoPoint":49,"geoPoint":53,"contacts":54},"University hospital, Lyon","Lyon","69000",{"type":33,"coordinates":50},[51,52],4.84789,45.74906,{"lat":52,"lon":51},[55,59],{"name":56,"role":17,"phone":57,"phoneExt":19,"email":58},"Emilien BERNARD, Dr","+33472357218","emilien.bernard@chu-lyon.fr",{"name":56,"role":44,"phone":10,"phoneExt":10,"email":10},{"facility":61,"status":10,"city":62,"state":10,"zip":63,"country":30,"countryCode":31,"cosmosGeoPoint":64,"geoPoint":68,"contacts":69},"university hospital, Tours","Tours","37044",{"type":33,"coordinates":65},[66,67],0.70398,47.39484,{"lat":67,"lon":66},[70,74],{"name":71,"role":17,"phone":72,"phoneExt":19,"email":73},"Philippe CORCIA, Pr","247473724","philippe.corcia@univ-tours.fr",{"name":71,"role":44,"phone":10,"phoneExt":10,"email":10},{"type":76,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100629772","characterization-of-platelet-molecular-profiles-in-als-for-the-identification-of-specific-diagnostic-biomarkers---a-pilot-study-100629772",false,"NCT07479017","Characterization of Platelet Molecular Profiles in ALS for the Identification of Specific Diagnostic Biomarkers - A Pilot Study","SLA-PlaQ","Inclusion Criteria:\n\nPatients with ALS:\n\n* Men or women aged 18 to 75\n* ALS diagnosed according to the El Escorial criteria\n* ALS diagnosis less than 3 months ago\n* Onset of symptoms defined as the time when muscle weakness was first observed by the patient less than 2 years ago\n\nControls with another motor neuron disease:\n\n* Men or women aged 18 to 75\n* Diagnosis of motor neuron disease \\\u003C 3 months\n\nExclusion Criteria:\n\n* Genetic variants associated with ALS\n* Pregnant or breastfeeding women\n* Treatment with oral or injectable anticoagulants, antiplatelet agents (EXCEPT aspirin at the maximum authorized dosage of 160 mg per day)\n* Uncontrolled diabetes\n* Persons deprived of their liberty by judicial or administrative decision\n* Persons subject to legal protection measures: guardianship or curatorship\n* Opposition to data processing","ALL","18 Years","75 Years",{"count":88,"type":89},60,"ESTIMATED","OBSERVATIONAL","The search for diagnostic biomarkers that can be used routinely is a major challenge to manage Amyotrophic lateral sclerosis (ALS) in order to characterize the pathophysiology and accelerate the management of the disease. Some non-specific biomarkers have been proposed (Neurofilaments, TDP-43) but their diagnostic value remains controversial. This study aims to identify ALS-specific platelet biomarkers using targeted and untargeted multi-omic approaches, in order to enable differential diagnosis between ALS and other motor neuron diseases.",[93],"ALS (Amyotrophic Lateral Sclerosis)",[95,96],"diagnostic biomarkers","platelet molecular profiles","NOT_YET_RECRUITING","2026-03-12",{"date":100,"type":101},"2026-03-18","ACTUAL",{"date":103,"type":89},"2026-04",{"date":105,"type":89},"2027-08",{"name":5,"class":6},3]